State drug importation programs will work with the FDA, not outside of it

A world map made by white tablets


July 16, 2019 – It does not seem to matter how angrily President Trump tweets, how pointedly House Speaker Nancy Pelosi lobs a critique, or how shrewdly health secretary Alex Azar drafts a regulatory change. The pharmaceutical industry is still winning in Washington.

In the past month alone, drug makers and the army of lobbyists they employ pressured a Republican senator not to push forward a bill that would have limited some of their intellectual property rights, according to lobbyists and industry representatives.


Be the first to comment

Leave a Reply

Your email address will not be published.